CXCR3 and melanoma: Penetration of melanoma cells could be significantly decreased when CXCL9 was preincubated with anti-CXCL9 antibody (Figure 5C) or when the melanoma cells were treated with anti-CXCR3 antibody for 1 h (Figure 5D) before the challenge of the EC monolayer.